Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
Perambakam S, Hallmeyer S, Reddy S, Mahmud N, Bressler L, DeChristopher P, Mahmud D, Nunez R, Sosman JA, Peace DJ. Perambakam S, et al. Among authors: mahmud d, mahmud n. Cancer Immunol Immunother. 2006 Sep;55(9):1033-42. doi: 10.1007/s00262-005-0090-x. Epub 2005 Nov 10. Cancer Immunol Immunother. 2006. PMID: 16283303 Free PMC article. Clinical Trial.
Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study.
Patel P, Aydogan B, Koshy M, Mahmud D, Oh A, Saraf SL, Quigley JG, Khan I, Sweiss K, Mahmud N, Peace DJ, DeMasi V, Awan AM, Weichselbaum RR, Rondelli D. Patel P, et al. Among authors: mahmud d, mahmud n. Biol Blood Marrow Transplant. 2014 Dec;20(12):2034-41. doi: 10.1016/j.bbmt.2014.09.005. Epub 2014 Sep 16. Biol Blood Marrow Transplant. 2014. PMID: 25234438 Free article. Clinical Trial.
A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma.
Patel P, Oh AL, Koshy M, Sweiss K, Saraf SL, Quigley JG, Khan I, Mahmud N, Hacker E, Ozer H, Peace DJ, Weichselbaum RR, Aydogan B, Rondelli D. Patel P, et al. Among authors: mahmud n. Leuk Lymphoma. 2018 Jul;59(7):1666-1671. doi: 10.1080/10428194.2017.1390231. Epub 2017 Oct 25. Leuk Lymphoma. 2018. PMID: 29065747 Clinical Trial.
Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N, Quigley J, Hoffman R, Jessop E, Beri R, Rondelli D. Chunduri S, et al. Among authors: mahmud n. Bone Marrow Transplant. 2006 Oct;38(7):477-82. doi: 10.1038/sj.bmt.1705480. Bone Marrow Transplant. 2006. PMID: 16980995 Clinical Trial.
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH, Mahmud N, Hurter E, Beri R, Rondelli D. Chunduri S, et al. Among authors: mahmud n. Bone Marrow Transplant. 2008 Jun;41(11):935-40. doi: 10.1038/bmt.2008.13. Epub 2008 Feb 11. Bone Marrow Transplant. 2008. PMID: 18264144 Clinical Trial.
397 results